Important update for Pharmeasy investors

18 November 2021

After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy.

Pharmeasy Consolidated Results (including all subsidiaries) as per March,2021

Total Revenue => ₹4,363.2 cr 

Total Consolidated Loss (including all subsidiaries) => ₹1,548.5 cr

Total Debt on 30th June,2021 => ₹2,772.61 cr

This means on every 1 cr sale of medicine, lab tests (including all subsidiaries), company incur a loss of 35.49 Lacs.

People should be cautious while investing in Pharmeasy stocks at such steep valuations or exit before the stock crashes.